Get the Stockscreener App
2.18
1.00%
-0.022
After Hours:
2.18
Phio Pharmaceuticals Corp stock is traded at $2.18, with a volume of 66,605.
It is down -1.00% in the last 24 hours and up +0.00% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$2.202
Open:
$2.2
24h Volume:
66,605
Relative Volume:
0.07
Market Cap:
$12.48M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.2673
EPS:
-8.156
Net Cash Flow:
$-11.09M
1W Performance:
-7.63%
1M Performance:
+0.00%
6M Performance:
+25.29%
1Y Performance:
-18.66%
1-Day Range:
$2.17
$2.25
1-Week Range:
$2.17
$2.45
52-Week Range:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
2.18 | 12.61M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
What earnings revisions data tells us about Phio Pharmaceuticals Corp.July 2025 Selloffs & Risk Managed Investment Signals - newser.com
Will Phio Pharmaceuticals Corp. stock see insider buyingJobs Report & Growth Oriented Trading Recommendations - newser.com
Analyzing Phio Pharmaceuticals Corp. with multi timeframe chartsTrade Entry Report & Accurate Technical Buy Alerts - newser.com
Combining price and volume data for Phio Pharmaceuticals Corp.Market Sentiment Report & Daily Stock Trend Reports - newser.com
Published on: 2025-10-10 04:55:45 - newser.com
Can trapped investors hope for a rebound in Phio Pharmaceuticals Corp.Portfolio Growth Summary & Community Verified Trade Signals - newser.com
Automated trading signals detected on Phio Pharmaceuticals Corp.Weekly Trend Report & Safe Capital Growth Plans - newser.com
Analyzing drawdowns of Phio Pharmaceuticals Corp. with statistical toolsJuly 2025 Fed Impact & Consistent Profit Alerts - newser.com
Real time pattern detection on Phio Pharmaceuticals Corp. stockJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
Phio Pharmaceuticals Announces New Manufacturing Agreement - MSN
What’s next for Phio Pharmaceuticals Corp. stock priceJuly 2025 Recap & Safe Capital Growth Stock Tips - newser.com
What makes Phio Pharmaceuticals Corp. (44R1) stock appealing to growth investorsPortfolio Gains Report & Daily Technical Stock Forecast Reports - newser.com
Is Phio Pharmaceuticals Corp. stock a safe buy before earningsTrade Performance Summary & Target Return Focused Stock Picks - newser.com
Phio Pharmaceuticals (NASDAQ:PHIO) Shares Down 0.4% – Here’s What Happened - Defense World
Morning Market Movers: SPRB, LXEO, BMEA, Seeing Big Swings - RTTNews
Published on: 2025-10-06 06:48:09 - newser.com
Detecting support and resistance levels for Phio Pharmaceuticals Corp.Price Action & Real-Time Volume Trigger Notifications - newser.com
Earnings visualization tools for Phio Pharmaceuticals Corp.July 2025 Selloffs & Weekly Watchlist for Consistent Profits - newser.com
Phio Pharmaceuticals Corp 44R1 Stock Analysis and ForecastSupport Level Holds & Free Discover Breakout Stocks Early - earlytimes.in
What drives Phio Pharmaceuticals Corp 44R1 stock priceGlobal Trade Effects & Exceptional Return Capital - earlytimes.in
Risk adjusted return profile for Phio Pharmaceuticals Corp. analyzedRate Hike & Low Drawdown Investment Strategies - newser.com
Biotech Stocks Rally After Hours On Trial Progress And Key Updates - RTTNews
Is Phio Pharmaceuticals Corp 44R1 a good long term investmentGeopolitical Risk Analysis & Build Winning Strategies With Zero Cost - earlytimes.in
What drives Phio Pharmaceuticals Corp stock priceTechnical Breakout Signals & Superior Trading Portfolio - earlytimes.in
Phio Pharmaceuticals Stockholders Approve Key 2025 Proposals - MSN
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - Newsfile
Biotech Breakthrough: Phio's INTASYL Cancer Treatment Shows Positive Results in Skin Cancer Trial - Stock Titan
Momentum divergence signals in Phio Pharmaceuticals Corp. chartJuly 2025 Action & Weekly Setup with High ROI Potential - newser.com
Technical signs of recovery in Phio Pharmaceuticals Corp.Index Update & Reliable Intraday Trade Plans - newser.com
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phio Pharmaceuticals Corp Stock (PHIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 21 '25 |
Buy |
1.77 |
3,000 |
5,310 |
22,449 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):